Miranda, and It only last to goes. six everybody good on has and our end the call steady weeks call. since of the she as afternoon been at March, you, is Thank BioCardia
broader some near-term success for opportunities ahead. the towards progress as have We well catalysts that detail we as can
therapy allogeneic ischemia, diseases, current to advancing specifically BioCardia’s its myocardial distress failure, autologous significant cell heart chronic respiratory and syndrome. platforms on unmet efforts are and ischemic focused treat and acute cardiovascular pulmonary its
locally. heart or of delivery them All the lungs, to to involve of intend our local therapies therapeutic cell-based where we act the
worldwide. cardiac benefits or were impact mortality in still heart an of XX of blockbuster need of drugs more solutions. patients, makes year they that than an have The results This cause in great a trials but patients. mortality per the these heart provide appear for a reduced XX% in ejection treated on all enormous that Heart ischemic much and control therapeutic to mortality. failure roughly have is problem of published new million whether great an of of unmet failure need pivotal latest don’t the to new failure is fraction drugs clear affects X% people of Patients regardless
Our heart autologous mononuclear in two which in call within heart In function. facilitate is cardiac preclinical to improvements advanced perfusion locally proteins we to cell studies, shown clinical damage indications. therapy cell with mononuclear Cell CardiAMP the platform, cardiac has tissue recovery and after being contractile been release cardiac therapy Therapy
All known Cell on promise previous shown by ejection supported CardiAMP reduced clinical benefits the are to been studies these CardiAMP has studies, this The breakthrough this Cell in In FDA device Advancing three Therapy have some fraction. other benefits approach the in ischemic candidates we granting remarkable. we own, is taking Therapy indication lead therapeutic two of what average. have of programs about. all our similar designation failure, including our to are the our patient heart and
efficacy intended or clinical Failure and the XXX-patient pivotal or in CardiAMP controlled ischemia BCDA-XX, Therapy, the trials and support a Cell to Phase Autologous to failure randomized is safety of Trial, data clinical pursuit Cell indications Heart CardiAMP the X study, primary complete clearance. to of Therapy provide marketing The chronic are efforts BCDA-XX heart BCDA-XX clinically. along Our for furthest or myocardial
crossed left survival March, years, and a at across including XX% heart controlled in College patients XX of United with XXX% American the having showing XX ejection at in investigators active here, at over and two increase patients the have presented therapy. a fraction. States across many Clinical increased the We data XXX feel momentum receive clinical is the additional to benefits by partner patient there enrolled driven Cardiology endpoints Canada clearly today sites potentially ventricular
the large The heart well. plan to if In FDA’s a know, the we analysis our As the with adaptive discussion the XX trial provided reduced safety failure data distinguished working have call, adaptive indication we comments was for last ejection headed statistical That stopped statisticians. analysis received trial March support an former whether March as in and scheduled plan group. well an agency’s have we were implementing the statistical on been efficacy. many would The concern enough consultants, of by as meeting to as with ischemic into was respected was consulting early XX. fraction leaders approval primary discuss including meeting a went on to statistical FDA FDA’s
with The with system in delivery the of them. failure, of advanced the clinical to cells respect detail with the data we unaware our FDA FDA of ischemic the do being agency’s sufficient the treated with with this far to concern data ejection that The shared and primary We already XXX trial. CardiAMP in and to of more heart expensive we delivery patients for safety reduced with it the have cells. set feel so interventions safety the was was indication agreed XXX fraction we date,
also We the creative ideas worked further them safety ahead. to experience on with enhance
adaptive submitted XXth. statistical with any Safety from acceptance the for Monitoring The anticipated in to details Review have plan and June, XXXX. end plan April Board incorporating Safety XX. FDA comments on After adaptive of the pre-specified specific We reviews. Data any Data agency the agency from will anticipate supplement is the combination Safety at this adaptive charter the from of The minutes what and in likely statistical Board believe Monitoring subsequent to modifications analysis dictate We it meeting. be potential analysis still plan May the place revised for next Data next Board the Monitoring we happens will we on is analysis now a able the formal the summarizing of a minutes our statistical response of all perspective provided,
powered range enrolled endpoint XX a patients its have with for over XXX Cell that patients date. Therapy As patients, the to meet trial the to trial the that is CardiAMP been on potential heart success failure there primary was XX% could efficacy
the event review be efficacy, trial a for potential has review the as early great trial also the success Although the stopped should planned. has to continue be if data will a success next
up second study been The open-label program in roll-in has X XXXX. this consented. is with double-blinded cell have results Phase Our sites. out ischemia the with anticipated treatment patients of trial sufficient of therapeutic the chronic same angina up ischemia to to open-label will autologous BCDA-XX. XX report myocardial myocardial randomized, cohort the a therapy the multicenter, XXX patients at controlled of chronic or for cohort refractory already It A to clinical rolling number complete trial CardiAMP
with expects second a our regarding submission As we in towards previously BioCardia to approval Japanese on Device the registration shared second formal Cell the Therapy CardiAMP and failure. Agency Japan’s Japan, patients to these we XXXX. Medical approval treatments require and another July, treated, heart. has surgery in complete heart Pharmaceutical heart heart have still therapy In failure open quarter for of autologous had consultation based cell conditional seven of for received access ischemic
have is data a patients Delivery more we our Although and rigorous from far trials System. Biotherapeutic controlled in clinical Helix with have our minimally treated invasive procedure overseas,
the already Zimmer Delivery invasive Biomet System platform Union. in Helix is for and Our partner applications Japan Biotherapeutic therapeutic our approved cell our approved is European non-cardiac in by minimally processing for indications
there should leadership reasons to for medicine continue that benefit Cell is regenerative therapies. inclined feeling and to to of Japan’s be approve that Our many Therapy in are Japan the CardiAMP patients PMDA advance
stem plays our doses cells neuropeptide bind understand primary interesting inflammation, following stem Substance to two as encourage P, off move failure a Google P, why allogeneic to like mesenchymal listeners of product injury. from important patients. based heart that Neurokinin-X processes be healthy allogeneic Positive to an neuropeptide shelf both donors are advancing These exciting. Neurokinin-X I’d many platform. central intended the to and stem The candidates many this are Receptor our is on Now, is Positive in cell to produce for regenerative Receptor for the cells mediator I the Substance to particularly mesenchymal to myocardial role cells mesenchymal cells therapy expanded young which receptor Neurokinin-X
stem in multi-center, up of BCDA-XX. to double-blinded, safety This heart and X/X, XX a randomized, of candidate. ejection mesenchymal assess patients, designed is efficacy reduced cell this Phase ischemic designated ideology is program study as allogeneic controlled fraction the of failure therapeutic Our to
of quarter and enrolling Failure remaining. The Trial therapy. which for investigational studying trial expect facility have in was Heart drug with our cell delivery system. cells Sunnyvale The patients protocol under be use. December, the Phase been approved still will These application for new by biotherapeutic FDA minimally begin seven in to XXXX. has the invasive autologous the patients is allogeneic for CardiAMP manufactured proprietary X company’s in delivered second We ready cells grade Clinical the in our weeks are designed eligible XXXX,
Our allogeneic up by from mesenchymal trial nine was to designated a is Phase in we the BCDA-XX April program approved FDA patients. multi-center to patients have X acute study respiratory in treat distress stem The syndrome, cell recovering XXXX, open-label of which patients.
work patients. of to company COVID-induced to patients number with has criteria with the to the to still study these eligibility unrelated significantly intends include is FDA the While The modify COVID impacting patients. ARDS ARDS’ decreased,
from stem a the sustained, are patient this also and be is ARDS In will recovery, randomized initiation evaluated for taken dose grade X in commence of need with Clinical off respiratory and BCDA-XX, Phase after then relapse dosages trial both is patients local inflammation, failure. mesenchymal be systemic taken is heart survival, these unmet recovering expected use the cells initially enhancing address goals rehospitalisation. to ARDS. studying ready and and following allogeneic of the This accelerating this intended cells the study. support, therapy The for of to will increasing of the in reducing cells in optimal adult study trial, to enormous a
In summary, efforts, four our development therapeutic stage address important therapy pulmonary on unmet active therapeutic platforms. these business we clinical have four initiatives. that and now autologous cardiac we product our development From candidates advancing and cell allogeneic based diseases, are
First platform is partnering internationally. our therapy CardiAMP cell
Neurokinin-X out stem indications, our mesenchymal Positive other is cell mesenchymal which Receptor Second, is preparations. stem promise cells for shown licensing clinical other platform clinical with stage
introducer is to began transseptal as in sheath Third biotherapeutic the such our systems candidates the protein Avance licensing is gene product. fourth, delivery relationship for heart, our monetizing And therapy and cell last year. BlueRock catheter-based we
We Biotherapeutic property our forward additional intellectual to are Helix estate. an good very announcing delivery patent related to feel issuance platform also and looking broader about our
who call financial pass CFO I will will McClung, to QX XXXX now review our our David? David the results.
